Loading…
Cellyan Biotechnology Co., Ltd is projected to decline to $0.5156 by 2027, a -5% move from its current price of $0.5419. HKPD is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $0.5194 | $0.5417 | $0.5649 | -0.04% |
| May 30 | $0.5102 | $0.5414 | $0.5746 | -0.08% |
| May 31 | $0.5033 | $0.5412 | $0.582 | -0.13% |
| Jun 1 | $0.4974 | $0.541 | $0.5884 | -0.17% |
| Jun 2 | $0.4923 | $0.5408 | $0.594 | -0.21% |
| Jun 3 | $0.4877 | $0.5405 | $0.5991 | -0.25% |
| Jun 4 | $0.4835 | $0.5403 | $0.6038 | -0.29% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.4835 | $0.5403 | $0.6038 | -0.29% |
| Week 2 | $0.4604 | $0.5387 | $0.6304 | -0.59% |
| Week 3 | $0.4431 | $0.5371 | $0.6511 | -0.88% |
| Week 4 | $0.4289 | $0.5356 | $0.6688 | -1.17% |
| Week 5 | $0.4165 | $0.534 | $0.6845 | -1.46% |
| Week 6 | $0.4056 | $0.5324 | $0.6989 | -1.75% |
| Week 7 | $0.3957 | $0.5308 | $0.7122 | -2.04% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Cellyan Biotechnology Co., Ltd is an investment holding company that engages in the over the counter (OTC) pharmaceutical business in Hong Kong and Mainland China. The company provides OTC pharmaceutical cross-border procurement and distribution and e-commerce supply chain services. It also offers custom clearance, drugs enlisting, warehouse, and other logistics services.
It serves e-commerce platform logistics partners, merchants, and pharmaceutical distributors. The company was formerly known as Hong Kong Pharma Digital Technology Holdings Limited and changed its name to Cellyan Biotechnology Co., Ltd in December 2025. Cellyan Biotechnology Co., Ltd was incorporated in 2023 and is based in Yau Tong, Hong Kong.
Cellyan Biotechnology Co., Ltd (HKPD) is the asset with a current price of $0.53 and a market cap of $12.45M, ranking 5099 by market size. The stock trades in the Healthcare space and carries a modest market position within its sector. The current price sits near technical support and sits below longer-term moving averages, reflecting a bearish tone in near-term trading.
The near-term outlook is informed by the forecast, which shows a flat to modestly range-bound path through 2026 and a shift toward stronger upside driven by later years.
A major floor 26.1% below — a decisive break under it would weaken the trend.
Price is testing support right now (2.2% away) — a key level to hold.
The nearest ceiling, 34.7% above — a clean break opens room to run.
A major ceiling 58.3% above — clearing it would confirm fresh momentum.
Key HKPD support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of HKPD market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.5406 | Buy | $0.543 | Sell |
| MA 10 | $0.552 | Sell | $0.556 | Sell |
| MA 20 | $0.5946 | Sell | $0.5806 | Sell |
| MA 50 | $0.6167 | Sell | $0.6223 | Sell |
| MA 100 | $0.6826 | Sell | $0.7038 | Sell |
| MA 200 | $0.9166 | Sell | $0.9057 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 41.64 | Neutral |
| Stoch RSI (14) | 48.11 | Neutral |
| CCI (20) | -73.89 | Neutral |
| Williams %R (14) | -89.09 | Info |
| MACD (12,26,9) | -0.01 | Sell |
| ROC (12) | -12.86 | Sell |
| Bollinger %B (20,2) | 0.25 | Neutral |
| Stochastic %K (14) | 10.91 | Buy |
| TRIX (15) | -0.51 | Sell |
| Awesome (5,34) | -0.08 | Sell |
| Ultimate (7,14,28) | 46.20 | Neutral |
| Momentum (10) | -0.02 | Sell |
| Aroon Osc (25) | -88.00 | Sell |
| Hull MA (9) | 0.53 | Buy |
| ADX (14) | 15.82 | Neutral |
| ATR (14) | 0.02 | Info |
The 30-day technical picture is bearish, with RSI14 at 40. The stock’s near-term momentum remains subdued as it edges toward support at $0.53 and faces resistance at $0.73. The 30-day range spans from $0.3958 to $0.7097, offering limited price capacity within that window.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.512 | $0.5419 | $0.6755 | 0% | Neutral | |
| $0.3836 | $0.5156 | $0.7466 | -5% | Neutral | |
| $0.3388 | $0.4778 | $0.7298 | -12% | Neutral | |
| $0.2831 | $0.4159 | $0.6622 | -23% | Bearish | |
| $0.3271 | $0.4985 | $0.822 | -8% | Neutral | |
| $0.3751 | $0.5916 | $1.01 | +9% | Neutral | |
| $0.3898 | $0.6352 | $1.11 | +17% | Neutral | |
| $0.3901 | $0.6556 | $1.17 | +21% | Bullish | |
| $0.3227 | $0.5587 | $1.02 | +3% | Neutral | |
| $0.3279 | $0.5845 | $1.09 | +8% | Neutral | |
| $0.3895 | $0.7967 | $1.62 | +47% | Bullish | |
| $0.5883 | $1.31 | $2.99 | +141% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $0.512 | $0.5419 | $0.6444 | +0.00% |
| June 2026 | $0.4623 | $0.5505 | $0.6767 | +1.59% |
| July 2026 | $0.4318 | $0.5215 | $0.655 | -5.27% |
| August 2026 | $0.4173 | $0.5095 | $0.6505 | -2.30% |
| September 2026 | $0.4219 | $0.52 | $0.6727 | +2.05% |
| October 2026 | $0.4069 | $0.5057 | $0.6622 | -2.74% |
| November 2026 | $0.3881 | $0.4859 | $0.6428 | -3.92% |
| December 2026 | $0.4009 | $0.5056 | $0.6755 | +4.05% |
Click any year to see its month-by-month HKPD forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Cellyan Biotechnology Co., Ltd's 2026 outlook centres on $0.5419, within a $0.512 to $0.6755 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, HKPD could reach as high as $0.7466, with a base case around $0.5156 and support toward $0.3836 — roughly -5% from $0.5419. A consolidation phase looks the most probable path here.
Expect HKPD to range from $0.3388 to $0.7298 through 2028. The $0.4778 average target implies a -12% move from current prices. That is -7% versus the projected 2027 average. Price action looks broadly range-bound.
The HKPD price prediction for 2029 points to an average of $0.4159 (low $0.2831, high $0.6622) — a potential decline of -23% on today's $0.5419. Expect choppier, lower action through this leg of the cycle.
In 2030, HKPD is projected to trade between $0.3271 and $0.822, averaging $0.4985 — a potential decline of -8% from today's $0.5419. That is up +20% on the projected 2029 average. Price action looks broadly range-bound.
Cellyan Biotechnology Co., Ltd's 2031 outlook centres on $0.5916, within a $0.3751 to $1.01 range. That is up +19% on the projected 2030 average. That marks a +9% change versus current levels. A consolidation phase looks the most probable path here.
By 2032, HKPD could reach as high as $1.11, with a base case around $0.6352 and support toward $0.3898 — roughly +17% from $0.5419. Price action looks broadly range-bound.
Expect HKPD to range from $0.3901 to $1.17 through 2033. The $0.6556 average target implies a +21% move from current prices. That is up +3% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The HKPD price prediction for 2034 points to an average of $0.5587 (low $0.3227, high $1.02) — a potential gain of +3% on today's $0.5419. Price action looks broadly range-bound.
In 2035, HKPD is projected to trade between $0.3279 and $1.09, averaging $0.5845 — a potential gain of +8% from today's $0.5419. That is up +5% on the projected 2034 average. A consolidation phase looks the most probable path here.
Cellyan Biotechnology Co., Ltd's 2040 outlook centres on $0.7967, within a $0.3895 to $1.62 range. That is up +36% on the projected 2035 average. That marks a +47% change versus current levels. Momentum favours further upside here.
By 2050, HKPD could reach as high as $2.99, with a base case around $1.31 and support toward $0.5883 — roughly +141% from $0.5419. Buyers look set to stay in control over this stretch.
Investing $1,000 in HKPD today (≈ 1,845.358922 HKPD) could be worth
$2,412.47
+$1,412.47 (+141%) by 2050 · US Dollar
Based on the average projected HKPD price of $1.31 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in HKPDwould be worth at today's price.
$1,000 invested in HKPD on May 27, 2025 (≈ 833.3333 HKPD) would be worth
$451.58
-$548.42 (-54.8%) today · 0.45× · US Dollar
Based on a HKPD entry price of $1.2 vs. today's $0.5419.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.541 | $1,001.66 | +0.2% |
| 1 month ago | $0.66 | $821.06 | -17.9% |
| 3 months ago | $0.65 | $833.69 | -16.6% |
| 6 months ago | $0.988 | $548.48 | -45.2% |
| 1 year ago | $1.2 | $451.58 | -54.8% |
| All time (1.4y) ago | $2.82 | $192.16 | -80.8% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our HKPD forecast.
Our base-case forecast reaches $1.10 around 2050.
Implied market cap at $1.10: $17.98M
The multi-year forecast shows a mixed but increasingly bullish path toward the end of the period. In 2026 the average price is $0.53 with a min of $0.512 and a max of $0.672, yielding 0% ROI and a Neutral sentiment. The trajectory through 2029 remains negative at times (2027 min $0.3672, avg $0.4991, max $0.732; ROI -5.8%; 2028 min $0.3218, avg $0.4604, max $0.7139; ROI -13.1%; 2029 min $0.2687, avg $0.4017, max $0.6505; ROI -24.2%; sentiment Bearish in 2029).
By 2030 the model shows a neutral path again (min $0.3083, avg $0.4795, max $0.8053; ROI -9.5). 2031-2033 project gradual upside with 2031 avg $0.5774 (ROI 8.9); 2032 avg $0.6222 (ROI 17.4); 2033 avg $0.6338 (ROI 19.6). 2034-2035 indicate modest gains (2034 avg $0.5393; ROI 1.8; 2035 avg $0.5684; ROI 7.2).
A notable shift occurs by 2040, with avg $0.7666, max $1.60 and ROI 44.6, signaling a bullish phase. The long-run projection for 2050 shows substantial upside, with min $0.5761, avg $1.28, max $2.94 and ROI 141.6, under a bullish sentiment. These figures reflect a forecast that emphasizes meaningful upside potential into the 2040s and beyond, tempered by higher near-term volatility.
Tap a question to reveal the answer.
The 2030 forecast shows min $0.3083, avg $0.4795, max $0.8053 with ROI -9.5% and a Neutral sentiment.
Near term shows mixed signals with 2026 avg $0.53 and ROI 0% (Neutral) and 2029 with ROI -24.2% (Bearish). Longer term shows positive ROIs in 2031-2033 (up to 19.6%), and strong upside by 2040 (ROI 44.6%) and 2050 (ROI 141.6%), but these are estimates and not guarantees.
The 2050 maximum forecast is $2.94, indicating potential upside beyond $2.00 in the distant outlook, but this is a forecast and not a guarantee.
Current price is $0.53 and market cap is $12.45M.
The near-term is bearish with RSI14 at 40. The price sits at support around $0.53 and faces resistance at $0.73, with a 30-day range of $0.3958 to $0.7097.
Cellyan Biotechnology Co., Ltd Community Discussion
0Share your Cellyan Biotechnology Co., Ltd price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.